Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

Turn Your $1,000 Into Over 2 Million Dollars With Their Help  at
http://www.stocksmastermind.com

On Monday we posted a Trade signal to buy crude oil at 72.65. If you
didn't get that signal find out how we did.

Monday's Trade Signal > http://tinyurl.com/yja7b2m

Check out the Crude Oil Trader > http://tinyurl.com/pxvr4d

Cool one..

my website blog: globeinvestors.info

u may learn more about my strategy via "Stock investing Top Topics "

and feel free to give advice

(NEP) China North Eastern Petroleum

Current P/E 4.61
Sales Growth*   +200.60%
Net Profit Margin       37.73%
Debt/Equity Ratio       0.16 (virtually no debt)
Only 20 million shares afloat (forward stock split is virtually a
guarantee)
Earning per share $.91
Book Value $10.9
Target price $21

Do your own research on this one, you will see amazing value here.
Other factors to consider:

1. Oil demand will continue to grow in China
2. At P/E 4.61, NEP is way under valued compared to other Chinese oil
companies trading at P/E of 13 and above, for example

(SNP) China petroleum is trading at 16.83 P/E @ $72.84 per share
(PTR) PetroChina is trading at 13.06 P/E @ $108 per share

Now take a look at (NEP) China North Eastern Petroleum, which is
trading at 4.61 P/E @ $4.25.  Not to mention, NEP has better balance
sheet, faster growth.

Nice trend today, higher volume too.  What caused this?

Nitro Petroleum (NTRO:OTCBB) is up over 50% again today. Thats over
500% since I bought in last week. Do your DD, this thing is going to
the moon I have no doubt. Company knows exactly how to take care of
their shareholders. Building big-time share value and making strong
plays. Seeing as how I'm a nice guy, I'll share that with you. Good
luck, get on board, and make that money

Maybe not chase it, but at least accumulate small allocations at a
time and be rewarded greatly in the future.

EROC (Eagle Rock Energy Partners)

HUSA (Houston American Energy Corporation)

DPTR (Delta Petroleum Corp)

PZE (Petrobras)

CPE (Callon Petroleum Company)

FTK (Flotek Industries)

If you want to miss the huge drop in stocks today and get a 50% check
TECO out, buy now at .04 sell at .06

On May 5, 12:20 pm, brad.bra...@gmail.com wrote:

Find the list of the Chinese ADRs with P/E here

http://www.diggsamachar.com/chineseadrs/chinesestocks/chineseadrsbype...

Patience An Asset In Stem Cell Work
Friday September 29, 7:00 pm ET
Peter Benesh

On July 19, President Bush issued his first and only veto since taking
office. He quashed a bill from Congress that would

have loosened restrictions on federal funds for embryonic stem cell
research.
The president's position is that because stem cell extraction destroys
the embryo, it ends a human life. So Bush blocked

legislation to expand federal funding of embryonic stem cell research,
putting him at odds with those who support more

funding -- including many Republicans.

The debate will be on some voters' minds in the Nov. 7 midterm
elections. Among those paying close attention are firms trying

to advance stem cell research -- and their shareholders' interests.

There's more than politics at play, says analyst Jose Haresco of
Merriman Curhan. Many scientists believe stem cells can halt

or reverse degenerative ailments such as Parkinson's, Lou Gehrig's
disease, multiple sclerosis and Alzheimer's. The broad

term is regenerative medicine.

Even damaged heart tissue might be regenerated by stem cells, Haresco
says. "It's not science fiction anymore."

While there are many types of stem cells -- including adult, umbilical
cord and autologous (the patient's own) -- much of the

media focus is on embryonic stem cells.

Embryonic cells are the most useful in medicine. They're also the most
controversial because of the political debate.

At least one company, Advanced Cell Technology, figures it can acquire
embryonic stem cells without crossing moral

boundaries.

Advanced Cell is an over-the-counter stock pursuing an Amex listing.
Using a technology similar to one used by in vitro

fertilization clinics, the firm has adapted a method to determine the
genetic health of embryos before they're implanted.

"It does not harm embryos," said Chief Executive William Caldwell.

He hopes the nondestructive technique will get the firm around the
federal funding ban.

Political Science

Federal money would give firms like Advance Cell a big boost, Haresco
says. One reason is that investors -- especially

institutional investors -- are hanging back from companies that
develop
stem cell therapies.

"(Investors) want clinical trials and advanced phase two data first,"
Haresco said.

Big pharmaceutical firms and major biotechs are holding back as well,
Caldwell says. "While all of them have stem cell

development labs someplace in the bowels of their organizations, they
are not putting capital into the sector."

These companies are nervous about the political and ethical climate
associated with the science, he says. The same holds true

for venture capital firms.

"VCs will take any risks -- except political," Caldwell said.

Despite the political fallout, there's plenty of research going on.
Foundations and other private funding sources are keeping

the work going. So are a handful of states, with California in the
lead. But there, too, politics has intruded.

California voters approved a 10-year, $3 billion stem cell research
fund in 2004. But because the money is tied up in a

wrangle about oversight, Republican Gov. Arnold Schwarzenegger tapped
the state's general fund for $150 million to finance

research.

Reflecting GOP tension, Schwarzenegger made the move on July 20 -- the
day after Bush's veto.

In 2005, the National Institutes of Health, which finances most basic
drug research in the U.S., committed $40 million to

stem cell research. The money was spread among 150 projects in the
U.S.
and abroad, most of it bound for universities.

If $40 million seems like a paltry sum, NIH officials say there's a
reason.

"It reflects the fact that the field is young," said Jim Battey,
chairman of the agency's stem cell task force.

Caldwell doesn't want to hear it. He calls the $40 million federal
contribution "a travesty."

With little in the way of federal money available, Advanced Cell was
forced to move to where the state money is. In February

the company relocated its headquarters to Alameda, Calif., from
Massachusetts.

"If you're going to survive, you must be close to the capital,"
Caldwell said.

Empty Street

Plenty of other companies are trying to turn the stem cell therapy
business into a success.

StemCells (NASDAQ:STEM - News), which develops therapeutics to treat
damaged or deteriorating organ systems, has followed a

path away from embryonic stem cells in developing a treatment for
Batten's disease, a rare genetic disorder in children that

is always fatal. Using nonembryonic human stem cells, the firm is
about
to launch a phase one trial on six children.

Targeting Batten's might seem odd, considering that as few as 600
Americans suffer from the condition. But StemCells Chief

Executive Martin McGlynn says doing so is the best way to make use of
available money and leverage the technology into other

diseases.

The challenge is convincing others, including Wall Street, of the
long-term payoff. McGlynn says institutional investors are

starting to pay attention to his firm, but the stock is still a
laggard. It trades for around $2 and has been trending down

for more than a year.

Nevertheless, McGlynn holds out hope that the tide will turn. "The
more
the story becomes clinical as opposed to scientific,

the easier it is for the Street to embrace it."

A handful of firms are moving into various clinical-trial phases.
Aastrom Biosciences (NASDAQ:ASTM - News) is running a phase

two trial of its bone repair technology based on adult stem cells.

Osiris Therapeutics (NASDAQ:OSIR - News) has a phase three trial of
its
stem cell drug for a life-threatening immune

condition that can hit cancer patients after a bone marrow transplant.

ViaCell (NASDAQ:VIAC - News) is monitoring subjects who received its
stem cell treatment for post-chemo-radiation blood

cancer patients. The stem cells in the phase one trial came from
umbilical cord blood.

Aastrom, Osiris and ViaCell have had a hard time earning much love
from
Wall Street. Aastrom's stock costs about $1, while

ViaCell's is about $4. Osiris, which went public at 11 on Aug. 4,
trades near 10.

One reason for optimism is that regenerative medicine has been proved
effective in at least one common procedure: the bone

marrow transplant. Patients with leukemia and lymphoma have stem cells
extracted from their own marrow, then re-injected

after radiation or chemotherapy has killed all the cancerous cells in
their blood.

Killing the cancer also kills the body's immune system. By using stem
cells from the patients' own marrow, they'll recover

their full immune systems, says Larry Couture, senior vice president
and founding director of the Center for Applied

Technology Development at City of Hope Cancer Center.

He says advances in these and other therapies might help soften
resistance to federal funding of embryonic stem cell

research.

"It's difficult to stop science," Couture said. "I think things will
change regardless of who takes office in the next couple

of years."

'Important Opportunity'

One result of a change in the political climate would be fewer
restrictions on federal money for embryonic stem cell

research, says Ross Muken, analyst with Deutsche Bank.

"The NIH budget under a new administration would likely be better
funded," he said.

Meanwhile, some well-established biotech supply firms are readying
themselves for growing demand for consumables needed in

stem cell research, Muken says. In this market, he puts Invitrogen
(NASDAQ:IVGN - News) and Applied Biosystems Group

(NYSE:ABI - News) in the lead. His employer does business with both.

Applied Biosystems officials sound optimistic about longer-term
prospects for stem cell technology.

"We see it as an important opportunity -- a niche that will grow,"
said
David Ginzinger, the firm's scientific operations

director.

The key is to enter the market at the right time, Muken says. "It will
be a big business. If companies don't get in early,

they may not get in late."

http://biz.yahoo.com/ibd/060929/health.html?.v=1

Reply   Reply with quote » ACTC ESRG

應該是進場時候了
詳情

www.BCLocation.com

有時間看熱鬧吧!!

 The only way to make money is to short my man.